Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.

ABSTRACT:

Purpose of this review

In order to combat the development of drug resistance, the clinical treatment of tuberculosis requires the combined use of several anti-tuberculosis (anti-TB) drugs, including isoniazid and rifampicin. Combinational treatment approaches are suggested by the World Health Organization (WHO) and are widely accepted throughout the world. Unfortunately, a major side effect of the treatment is the development of anti-tuberculosis drug-induced liver injury (AT-DILI). Many factors contribute to isoniazid- and rifampicin-mediated AT-DILI and genetic variations are among the most common factors. The purpose of this review is to provide information on genetic variations associated with isoniazid- and rifampicin-mediated AT-DILI.

Recent findings

The genetic variat

SUBMITTER: Bao Y 

PROVIDER: S-EPMC6241288 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature